Processing...
Clinical Trials for Pancreas Cancer
Search
Search
There are 216 active trials for advanced/metastatic pancreas cancer.
Click on a trial to see more information.
216 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.
ClinicalTrials.gov ID: NCT07090499
HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
HealthScout AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.
ClinicalTrials.gov ID: NCT07213791
HealthScout AI summary: Adults with advanced solid tumors including HNSCC, pancreatic adenocarcinoma, NSCLC, HR+/HER2− breast cancer post‑CDK4/6 inhibitor, or platinum‑resistant high‑grade serous ovarian/related cancers receive the oral CDK7 inhibitor GTAEXS617 (transcription/cell‑cycle regulator) as monotherapy or combined with standard-of-care regimens. Eligible patients have ECOG 0–1 and adequate organ function; study explores safety, PK, and preliminary activity with tumor biopsies required.
ClinicalTrials.gov ID: NCT05985655
HealthScout AI summary: Adults with advanced/metastatic colorectal adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma after at least one prior systemic therapy receive IV PHN-012, a first-in-human investigational antibody–drug conjugate (target undisclosed; exclusion suggests possible topoisomerase‑I payload). Open-label dose escalation with tumor-specific expansion; requires measurable disease, ECOG 0–1, adequate organs, and available tissue; excludes prior topo‑I ADCs, unstable CNS mets, and active/past ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07127874
HealthScout AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
HealthScout AI summary: Adults with homozygous MTAP-deleted solid tumors (ECOG 0–1) receive oral BAY 3713372, an MTAP-selective, second-generation PRMT5 inhibitor exploiting synthetic lethality, with monotherapy dose escalation and expansions in all MTAP-deleted tumors plus focused cohorts in NSCLC and PDAC. Expansion includes BAY 3713372 alone and in combinations for NSCLC and PDAC; key cardiac comorbidities are excluded.
ClinicalTrials.gov ID: NCT06914128
HealthScout AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326
HealthScout AI summary: This trial enrolls adults with advanced solid tumors or lymphoma that are refractory to standard therapies, whose tumors overexpress TrkA or harbor an NTRK1 gene fusion, to receive oral VMD-928, a highly selective irreversible TrkA inhibitor that acts via allosteric dimerization and inactivation of the target. Key exclusions include significant comorbidities and impaired drug absorption.
ClinicalTrials.gov ID: NCT03556228
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including NSCLC without actionable mutations and pancreatic ductal adenocarcinoma—to receive Mavrostobart (PT199), an investigational anti-CD73 antibody targeting adenosine-mediated immunosuppression, as monotherapy or in combination with PD-1 inhibitors and/or chemotherapy. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT05431270